The Patent Finder

Polynucleotides and Polypeptide Sequences Involved in Cancer

ADC Therapeutics S.A.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/CA2012/000296, filed Mar 28, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 8,216,582Polynucleotides and Polypeptide Sequences Involved in Cancer
In force
 · High confidence
UsedRemaining
ADC Therapeutics S.A.In forceHigh confidence
US 8,937,163Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof
In force
 · High confidence
ADC Therapeutics S.A.In forceHigh confidence
US 9,393,302Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof
In force
 · Medium confidence
ADC Therapeutics S.A.In forceMedium confidence
US 10,597,450Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof
In force
 · Medium confidence
ADC Therapeutics S.A.In forceMedium confidence
US 8,580,257Antibodies That Specifically Block the Biological Activity of Kidney Associated Antigen 1 (KAAG1)
Lapsed Nov 12, 2025 on the fee record
High confidence
ADC Therapeutics S.A.Lapsed Nov 12, 2025 on the fee recordHigh confidence
US 9,828,426Antibodies Against Kidney Associated Antigen 1 and Antigen Binding Fragments Thereof
Lapsed Nov 28, 2025 on the fee record
High confidence
ADC Therapeutics S.A.Lapsed Nov 28, 2025 on the fee recordHigh confidence
US 9,855,291Anti-Kidney Associated Antigen 1 (KAAG1) Antibodies
Lapsed Jan 2, 2026 on the fee record
High confidence
ADC Therapeutics S.A.Lapsed Jan 2, 2026 on the fee recordHigh confidence
Application 13/490,857Polynucleotides and Polypeptide Sequences Involved in Cancer
Abandoned
Abandoned May 20, 2015
ADC Therapeutics S.A.AbandonedAbandoned May 20, 2015
Application 14/690,562Polynucleotides and Polypeptide Sequences Involved in Cancer
Abandoned
Abandoned Jan 29, 2018
ADC Therapeutics S.A.AbandonedAbandoned Jan 29, 2018
Application 15/833,753Antibodies That Specifically Block the Biological Activity of a Tumor Antigen
Abandoned
Abandoned Sep 6, 2022
ADC Therapeutics S.A.AbandonedAbandoned Sep 6, 2022
2 more records in this group · Pro
10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 12, including 3 expired.
Upgrade to Pro
4 of these are in force and held by ADC Therapeutics S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited